圣地亚哥 - 生物制药公司ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)宣布,其处方药neffy®(肾上腺素鼻喷剂)现已在全美上市。美国食品药品监督管理局(FDA)上月批准了用于治疗体重超过30公斤(66磅)个体I型过敏反应(包括过敏性休克)的2毫克neffy。 通过neffyConnect项目和与在线药房BlinkRx的合作,符合条件的商业保险患者可以25美元的 ...

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

ARS Pharmaceuticals Inc (SPRY) stock saw a decline, ending the day at $14.77 which represents a decrease of $-0.09 or -0.61% from the prior close of $14.86. The stock opened at $14.97 and touched a ...

They didn’t cost any money this year, but we’re wondering what’s going to happen next year and the following years,” one ...

SAN DIEGO - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)已提交一份补充新药申请(sNDA),用于neffy® 1 mg,这是一种针对体重15至30公斤(33-66磅)儿童的无针式肾上腺素治疗,用于I型过敏反应,包括过敏性休克。此次提交是在FDA于2024年8月9日批准用于30公斤或以上患者的neffy 2 mg之后进行的。 该公司报告称,neffy ...

That said, seniors need to have some savings to be happy. No one can feel relaxed with money worries. Giving creates joy but ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ARS Pharmaceuticals Inc (SPRY) stock saw a modest uptick, ending the day at $14.05 which represents a slight increase of $1.00 or 7.66% from the prior close of $13.05. The stock opened at $13.1 and ...

Copyright © 2024 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.